Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro CorpABP · Entity 166815 | Chief Financial Officer | May 10, 2018 | May 10, 2018 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Financial Officer | February 12, 2025 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Corp
Report date May 10, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2026-12-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: (i) 41,637 of the shares underlying the option vested and became exercisable on September 6, 2017 and (ii) the remaining shares shall vest and become exercisable in 36 substantially equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: (i) 41,637 of the shares underlying the option vested and became exercisable on September 6, 2017 and (ii) the remaining shares shall vest and become exercisable in 36 substantially equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date.
X4 Pharmaceuticals, Inc
Report date February 12, 2025 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 850,000 |
Reported balance
After 2025-02-12 transaction · row 1
1 source rowRow 1 · 2025-02-12 · Grant · Acquired 850,000 · Balance 850,000 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2025 Filed Feb 14, 2025 16:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-005702 · wk-form4_1739567322.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 18:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 74,773 | $0.45 | $33,946.94 |
DisclosureSEC source: 0001628280-25-002708 · wk-form4_1738019736.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.447 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 74,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-002708 · wk-form4_1738019736.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,773 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 16:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 230,645 | $0.55 | $126,900.88 |
DisclosureSEC source: 0001628280-24-042545 · wk-form4_1728420276.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5144 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 16:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042545 · wk-form4_1728420276.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,645 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of the performance condition. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 17:19 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 52,500 | $0.88 | $46,347.00 |
DisclosureSEC source: 0001628280-24-010279 · wk-form4_1710191979.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.8649 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 17:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 523,414 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005384 · wk-form4_1708121388.xml · derivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,414 Underlying: Common Stock · 523,414 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 17:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 27,721 | $1.01 | $27,973.26 |
DisclosureSEC source: 0001628280-24-004263 · wk-form4_1707775417.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.07, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:42 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 230,645 | $0.73 | $168,370.85 |
DisclosureSEC source: 0001628280-23-036758 · wk-form4_1699044122.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,221 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.7911, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 17:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 230,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036471 · wk-form4_1698959058.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,866 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,641 | $1.89 | $4,991.49 |
DisclosureSEC source: 0001628280-23-024228 · wk-form4_1688587453.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,221 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.84 to $1.95 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents restricted stock units. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 16:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,417 | $1.93 | $10,454.81 |
DisclosureSEC source: 0001628280-23-023443 · wk-form4_1687810394.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,862 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:17 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,417 | $2.22 | $12,025.74 |
DisclosureSEC source: 0001628280-23-022473 · wk-form4_1686946623.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,279 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $2.14 to $2.39, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents restricted stock units. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 16:50 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 52,500 | $0.84 | $44,100.00 |
DisclosureSEC source: 0001628280-23-007722 · wf-form4_167874064200077.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,696 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.90, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents restricted stock units. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 17:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 27,721 | $0.93 | $25,780.53 |
DisclosureSEC source: 0001628280-23-003757 · wf-form4_167649914450211.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,196 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.91 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents restricted stock units. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 16:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 1,350,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001628280-22-029261 · wf-form4_166802894353588.xml · derivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2032-11-07 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 13:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 10,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-023323 · wf-form4_166092864529306.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,917 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 17:01 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018400 · wf-form4_165670924581616.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,751 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 16:14 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018047 · wf-form4_165636087288621.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,392 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 16:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,416 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-017438 · wf-form4_165549734296466.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,808 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.13, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 16:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004497 · wf-form4_164616893696670.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,224 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 27,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-002511 · wf-form4_164487375572326.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,224 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.52 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 10,832 | $5.10 | $55,243.20 |
DisclosureSEC source: 0001628280-21-017333 · wf-form4_162940478600346.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,945 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $4.98 to $5.35, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 08:18 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,641 | $6.64 | $17,536.24 |
DisclosureSEC source: 0001628280-21-013299 · wf-form4_162514188426351.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,777 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.50 to $6.78, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,417 | $7.01 | $37,973.17 |
DisclosureSEC source: 0001628280-21-012933 · wf-form4_162465141949892.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,418 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.89 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012933 · wf-form4_162465141949892.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,835 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,417 | $7.84 | $42,469.28 |
DisclosureSEC source: 0001628280-21-012477 · wf-form4_162396433610629.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,585 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.20, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012477 · wf-form4_162396433610629.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,002 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 15, 2021. One third of the shares will vest on June 15, 2022, and one third of the shares will vest on June 15, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 17:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 83,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-005667 · wf-form4_161670655632254.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,752 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 16:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 10,834 | $7.08 | $76,704.72 |
DisclosureSEC source: 0001628280-20-013832 · wf-form4_160080547296478.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,589 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.01 to $7.18, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012846 · wf-form4_159779615491282.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,423 F3 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 17, 2020. One third of the shares will vest on August 17, 2021, and one third of the shares will vest on August 17, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F4 · balance_after: Of the shares of common stock reported, 29,589 shares represent unvested restricted stock units. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012846 · wf-form4_159779615491282.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 14, 2020. One third of the shares will vest on August 14, 2021, and one third of the shares will vest on August 14, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 18,756 Shares represent unvested restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | Tax withholdingCommon Stock | 916 | $9.32 | $8,537.12 |
DisclosureSEC source: 0001628280-20-010103 · wf-form4_159363420470551.xml · nonDerivative · entry 2 Mostafa Adam S. · CIK 0001738081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,923 F3 · shares: Shares withheld by X4 Pharmaceuticals Inc. to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 1,725 | $9.04 | $15,594.00 |
DisclosureSEC source: 0001628280-20-010103 · wf-form4_159363420470551.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,839 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $9.19, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 15,847 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0000899243-19-017421 · doc4.xml · derivative · entry 2 Mostafa Adam S. · CIK 0001738081 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,847 Underlying: Common Stock · 15,847 shares Expires 2029-06-17 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on June 17, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 10,564 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017421 · doc4.xml · nonDerivative · entry 1 Mostafa Adam S. · CIK 0001738081 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,564 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's 2017 Equity Incentive Plan, with each restricted stock unit representing the contingent right to receive one share of common stock on the applicable vesting date. No amount was paid upon grant of the units. The restricted stock units vest in four equal annual installments on June 30, 2020, June 30, 2021, June 30, 2022 and June 30, 2023, subject to the Reporting Person continuing to provide services through each such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:28 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 62,633 | Not disclosed Strike: $10.44 | Not disclosed |
DisclosureSEC source: 0000899243-19-007821 · doc4.xml · derivative · entry 1 Mostafa Adam S. · CIK 0001738081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,633 Underlying: Common Stock · 62,633 shares Expires 2028-10-03 F2 · price: Reflects the Reporting Person's stock option to acquire 659,067 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on October 4, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 16:39 UTC Amendment | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 62,633 | Not disclosed Strike: $10.44 | Not disclosed |
DisclosureSEC source: 0000899243-19-007975 · doc4a.xml · derivative · entry 1 Mostafa Adam S. · CIK 0001738081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,633 Underlying: Common Stock · 62,633 shares Expires 2028-10-03 F2 · price: Reflects the Reporting Person's stock option to acquire 659,067 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on September 5, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to correct the vesting schedule of the option included in the Form 4 filed on March 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.